The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo
Open accessAbstract
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease (MPD) initiated by p210-BCR-ABL–mediated transformation of hematopoietic stem cells (HSCs). Inhibition of the ABL kinase alone is not sufficient to eradicate leukemic stem cells (LSCs). We have previously shown that the deficiency of Rac2 GTPase signaling, but not Rac1, in p210-BCR-ABL–transduced hematopoietic cells prolonged survival of mice with MPD. Here we demonstrate that absence of Rac2 GTPase prolongs survival of HSC-initiated, inducible Scl/p210-BCR-ABL (Scl/p210) binary transgenic mice, it induces apoptosis, and, unlike in normal HSC and progenitor (HSC/P), impairs LSC and progenitor (LSC/P) proliferation in vivo. As a result, Rac2 deficiency causes functional exhaustion of the LSC pool in vivo. This defect is not due to impaired interaction with the hematopoietic microenvironment as reflected by its unaltered adhesion, migration, and homing to recipient organs. In summary, Rac2 deficiency exhausts the LSC pool in vivo through impairment of oncogene-induced proliferation and survival signals.
Overview
CoChat Summary
Written by AI from the paper’s full text.
TL;DR
Rac2 GTPase deficiency prolongs survival in an HSC-initiated inducible Scl/p210-BCR-ABL mouse model of CML by reducing leukemic stem/progenitor proliferation and increasing apoptosis, leading to functional exhaustion of the leukemic stem cell pool. The defect is not explained by altered homing, adhesion, or migration.
Key findings
- Rac2 deficiency significantly prolonged survival of Scl/p210 mice; Scl/p210 mice showed 50% mortality after 8 months, and Rac2 deficiency alone significantly prolonged survival in vivo.
- Scl/p210;Rac2−/− mice had lower tumor-initiating LK and LSK cell content despite similar BCR-ABL expression (average ΔCt Scl/p210 = 7.00 vs Scl/p210;Rac2−/− = 6.01; 4 mice per group). Circulating LSK cells were 2-fold reduced (0.014% ± 0.007% vs 0.036% ± 0.02%; P < .05, n = 10 mice per group).
- Absence of Rac2 significantly reduced proliferation of Scl/p210 cells to levels similar to nonleukemic HSC/P, but did not modify proliferation of normal LK and LSK cells in vivo; Rac2 deficiency also induced apoptosis.
- Scl/p210;Rac2−/− cells showed significantly reduced long-term HSC engraftment and could not compete with normal HSCs in primary-to-secondary competitive repopulation, while homing to BM and spleen, adhesion, and migration were not altered.
Methods
- FVB/N-backcrossed Scl/p210-BCR-ABL mice were crossed with C57Bl/6 Rac2−/− mice to generate F2 Scl/p210;Rac2−/− mice; Rac-expressing Scl/p210 littermates were controls. Mice weaned from doxycycline for 3 months were used for assays.
- Assays included qPCR for genomic b3a2 and murine ApoB, in vivo BrdU incorporation for proliferation, activated caspase 3 flow cytometry for survival, adhesion and migration assays, homing assays, and competitive repopulation using CD45.1+ B6.SJLPtprca Pep3b/BoyJ recipients and competitor cells.
- Engraftment after transplantation was measured by chimera assessment by flow cytometry and qPCR of peripheral blood.
Limitations
- The paper does not state limitations in a dedicated section.
- Evident from the text: findings are from a mouse transgenic model (Scl/p210;Rac2−/−) rather than human CML samples, and several supporting analyses are reported in supplemental figures.
- Evident from the text: the study tests Rac2 deficiency rather than a pharmacologic Rac2 inhibitor, so direct therapeutic targeting is not established here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
18 Own result · 9 Own interpretation · 8 Check pending · 5 No full text of the sources · 3 Not checked yet
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the absence of Rac2 significantly reduced proliferation of Scl/p210 to levels similar to nonleukemic HSC/P”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This defect is not due to impaired interaction with the hematopoietic microenvironment as reflected by its unaltered adhesion, migration, and homing to recipient organs.”
- Also stated in: § Results and discussion · plain
“Scl/p210 and Scl/p210;Rac2−/− hematopoietic progenitors home to BM and spleen similarly”
- Also stated in: § Results and discussion · plain
“deletion of Rac2 did not affect the adhesion and migration-related transformation phenotype of Scl/p210 progenitors”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results and discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“unlike in normal HSC and progenitor (HSC/P), impairs LSC and progenitor (LSC/P) proliferation in vivo.”
- Also stated in: § Results and discussion · plain
“the absence of Rac2 significantly reduced proliferation of Scl/p210 to levels similar to nonleukemic HSC/P, but did not modify the proliferation of normal LK and LSK cells in vivo”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results and discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prolonged survival of Scl/p210;Rac2−/− mice was associated with lower content of tumor-initiating LK and LSK cells in vivo (Figure 1B-C)”
plainstates an associationn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Scl/p210;Rac2−/− cells showed significantly reduced long-term HSC engraftment”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 5
Create a free account to see these claims.
28 more claims
Create a free account to see all 43 claims and to verify the 11 references still open.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RAC activity has been implicated in the disease initiation and maintenance in various murine leukemia models, including BCR-ABL and MLL-AF9-driven transformation [29–32].”
From Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2 (2015) · cites this paper as [30]
In the citing paper
“RAC GTPases are necessary for development and maintenance of leukemia in various murine models, including BCR-ABL-mediated transformation [30–32].”
From Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2 (2015) · cites this paper as [30]
In the citing paper
“In particular, RAC2 was shown to be critical for the development of BCR-ABL-mediated malignancy [30,44].”
From Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2 (2015) · cites this paper as [30]
Citations
Cites
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Yilmaz, Ö. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature04703 · Cited by 1,113
Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL
Shivdasani, R. A., Mayer, E. L., & Orkin, S. H. (1995) · Nature · doi:10.1038/373432a0 · Cited by 938
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
Roberts, A. W., Kim, C., Zhen, L., Lowe, J. B., Kapur, R., Petryniak, B., Spaetti, A., Pollock, J. D., Borneo, J. B., Bradford, G. B., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80019-9 · Cited by 556
Self-citationHematopoietic Cell Regulation by Rac1 and Rac2 Guanosine Triphosphatases
Gu, Y., Filippi, M.-D., Cancelas, J. A., Siefring, J. E., Williams, E. P., Jasti, A. C., Harris, C. E., Lee, A. W., Prabhakar, R., Atkinson, S. J., et al. (2003) · Science · doi:10.1126/science.1088485 · Cited by 510
Self-citationBethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
Kogan, S. C., Ward, J. M., Anver, M. R., Berman, J. J., Brayton, C., Cardiff, R. D., Carter, J. S., de Coronado, S., Downing, J. R., Fredrickson, T. N., et al. (2002) · Blood · doi:10.1182/blood.v100.1.238 · Cited by 418
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
Krause, D. S., Lazarides, K., von Andrian, U. H., & Van Etten, R. A. (2006) · Nature Medicine · doi:10.1038/nm1489 · Cited by 349
Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization
Cancelas, J. A., Lee, A. W., Prabhakar, R., Stringer, K. F., Zheng, Y., & Williams, D. A. (2005) · Nature Medicine · doi:10.1038/nm1274 · Cited by 278
Self-citation
Cited by
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Neviani, P., Harb, J. G., Oaks, J. J., Santhanam, R., Walker, C. J., Ellis, J. J., Ferenchak, G. J., Dorrance, A. M., Paisie, C. A., Eiring, A. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68951 · Cited by 231
Nieborowska-Skorska, M., Kopinski, P. K., Ray, R., Hoser, G., Ngaba, D., Flis, S., Cramer, K., Reddy, M. M., Koptyra, M., Penserga, T., et al. (2012) · Blood · doi:10.1182/blood-2011-10-385658 · Cited by 177
Self-citationRho GTPases modulate malignant transformation of tumor cells
Orgaz, J. L., Herráiz, C., & Sanz‐Moreno, V. (2014) · Small GTPases · doi:10.4161/sgtp.29019 · Cited by 195
O’Hare, T., Deininger, M. W., Eide, C. A., Clackson, T., & Druker, B. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3314 · Cited by 150
RHO GTPases in cancer: known facts, open questions, and therapeutic challenges
Bustelo, X. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170531 · Cited by 89
New strategies to treat AML: novel insights into AML survival pathways and combination therapies
Nair, R., Salinas-Illarena, A., & Baldauf, H. (2020) · Leukemia · doi:10.1038/s41375-020-01069-1 · Cited by 87
The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells
Adane, B., Ye, H., Khan, N., Pei, S., Minhajuddin, M., Stevens, B. M., Jones, C. L., D’Alessandro, A., Reisz, J. A., Zaberezhnyy, V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.009 · Cited by 86
Shalapour, S., Hof, J., Kirschner‐Schwabe, R., Bastian, L., Eckert, C., Prada, J., Henze, G., von Stackelberg, A., & Seeger, K. (2011) · Haematologica · doi:10.3324/haematol.2011.047993 · Cited by 76
Mizukawa, B., Wei, J., Shrestha, M., Wunderlich, M., Chou, F.-S., Griesinger, A., Harris, C. E., Kumar, A. R., Zheng, Y., Williams, D. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351817 · Cited by 70
Self-citationActivation of the vascular niche supports leukemic progression and resistance to chemotherapy
Poulos, M. G., Gars, E. J., Gutkin, M. C., Kloss, C. C., Ginsberg, M. D., Scandura, J. M., Rafii, S., & Butler, J. M. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.08.003 · Cited by 59
Cancer stem cells: A stride towards cancer cure?
Sengupta, A., & Cancelas, J. A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22213 · Cited by 58
Self-citationNiche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cells
Schreck, C., Istvánffy, R., Ziegenhain, C., Landspersky, T., Ruf, F., Henkel, L., Gärtner, F., Vieth, B., Florian, M. C., Mende, N., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151414 · Cited by 56
Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
Berger, A., Sexl, V., Valent, P., & Moriggl, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2465 · Cited by 52
Sengupta, A., Durán, Á., Ishikawa, E., Florian, M. C., Dunn, S. K., Ficker, A. M., Leitges, M., Geiger, H., Díaz-Meco, M. T., Moscat, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103132108 · Cited by 52
Self-citationWnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia
Hasan, M. K., Yu, J., Widhopf, G. F., Rassenti, L. Z., Chen, L., Shen, Z., Briggs, S. P., Neuberg, D. S., & Kipps, T. J. (2018) · Blood · doi:10.1182/blood-2017-12-819383 · Cited by 49
Chang, K. H., Sánchez‐Aguilera, A., Shen, S., Sengupta, A., Madhu, M., Ficker, A. M., Dunn, S. K., Davis, A. K., Arnett, J. L., Santho, R. A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-361709 · Cited by 47
Self-citationGerboth, S., Frittoli, E., Palamidessi, A., Baltanás, F. C., Salek, M., Rappsilber, J., Giuliani, C., Troglio, F., Rolland, Y., Pruneri, G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.267 · Cited by 42
Chatterjee, S. S., Biswas, M., Boila, L. D., Banerjee, D., & Sengupta, A. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0493 · Cited by 41
Self-citationSinha, S., Biswas, M., Chatterjee, S. S., Kumar, S., & Sengupta, A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107570 · Cited by 40
Self-citationBmi1 reprograms CML B-lymphoid progenitors to become B-ALL–initiating cells
Sengupta, A., Ficker, A. M., Dunn, S. K., Madhu, M., & Cancelas, J. A. (2011) · Blood · doi:10.1182/blood-2011-06-359232 · Cited by 36
Self-citationSchemionek, M., Spieker, T., Kerstiens, L., Elling, C., Essers, M. A. G., Trumpp, A., Berdel, W. E., Müller‐Tidow, C., & Koschmieder, S. (2011) · Leukemia · doi:10.1038/leu.2011.366 · Cited by 35
Pak2 Regulates Hematopoietic Progenitor Cell Proliferation, Survival, and Differentiation
Zeng, Y., Broxmeyer, H. E., Staser, K. W., Chitteti, B. R., Park, S.-J., Hahn, S., Cooper, S. H., Sun, Z., Jiang, L., Yang, X., et al. (2015) · Stem Cells · doi:10.1002/stem.1951 · Cited by 31
Biswas, M., Chatterjee, S. S., Boila, L. D., Chakraborty, S., Banerjee, D., & Sengupta, A. (2019) · The FASEB Journal · doi:10.1096/fj.201801035r · Cited by 29
Self-citationWilliamson, A. J. K., Pierce, A., Jaworska, E., Zhou, C., Aspinall-O’Dea, M., Lancashire, L., Unwin, R. D., Abraham, S. A., Walker, M. J., Cadecco, S., et al. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.024604 · Cited by 23
Perrotti, D., Silvestri, G., Stramucci, L., Yu, J. E., & Trotta, R. (2016) · Current Drug Targets · doi:10.2174/1389450117666160615074120 · Cited by 22
Flis, S., Bratek, E., Chojnacki, T., Piskorek, M., & Skórski, T. (2019) · Cancers · doi:10.3390/cancers11101544 · Cited by 22
Yung, S., Ledran, M. H., Moreno, I., Conesa, A., Montaner, D. A., Dopazo, J., Dimmick, I., Slater, N. J., Marenah, L., Real, P. J., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr431 · Cited by 21
Etten, R. A. V., Koschmieder, S., Delhommeau, F., Perrotti, D., Holyoake, T. L., Pardanani, A. D., Mesa, R. A., Green, A. R., Ibrahim, A. R., Mughal, T. I., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.035675 · Cited by 21
Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2
Capala, M. E., Maat, H., Bonardi, F., van den Boom, V., Kuipers, J., Vellenga, E., Giepmans, B. N. G., & Schuringa, J. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128585 · Cited by 20
Jiao, B., Ren, Z., Liu, P., Chen, L., Shi, J., Dong, Y., Ablain, J., Shi, L. S., Gao, L., Hu, J.-P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222863110 · Cited by 20
Frat2 mediates the oncogenic activation of Rac by MLL fusions
Walf-Vorderwülbecke, V., de Boer, J., Horton, S. J., van Amerongen, R., Proost, N., Berns, A. J. M., & Williams, O. (2012) · Blood · doi:10.1182/blood-2012-05-432534 · Cited by 20
Hegde, S., Gasilina, A., Wunderlich, M., Lin, Y., Buchholzer, M., Krumbach, O. H. F., Akbarzadeh, M., Ahmadian, M. R., Seibel, W. L., Zheng, Y., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01455-3 · Cited by 15
Self-citationCapala, M. E., Vellenga, E., & Schuringa, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111568 · Cited by 11
Staehle, H. F., Pahl, H. L., & Jutzi, J. S. (2021) · Biomolecules · doi:10.3390/biom11121911 · Cited by 12
Capala, M. E., Pruis, M. G. M., Vellenga, E., & Schuringa, J. J. (2016) · Stem Cells and Development · doi:10.1089/scd.2015.0151 · Cited by 12
Nayak, R. C., Chang, K. H., Singh, A. K., Kotliar, M., Desai, M., Wellendorf, A. M., Wunderlich, M., Bartram, J. L., Mizukawa, B. E., Cuadrado, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30651-7 · Cited by 11
Self-citationSong, K., Wang, H., Wang, H., Wang, L., Mo, Q., Wu, S., & Liu, T. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9295-y · Cited by 10
Zhu, X., Li, Y., Luo, X., & Jia, F. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.016 · Cited by 10
Juan, W. C., & Ong, S. T. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00007-9 · Cited by 10
Bates, J. G., Salzman, J., May, D., Garcia, P. B., Hogan, G. J., McIntosh, M. W., Schlissel, M. S., & Brown, P. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037108 · Cited by 9
Rac1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome
Hu, T., Chong, Y., Lu, S., McGuinness, M. K., Williams, D. A., & Cowell, J. K. (2019) · Haematologica · doi:10.3324/haematol.2018.208058 · Cited by 9
Self-citationChronic myeloid leukemia stem cells and developing therapies
Donato, N. J., & Peterson, L. F. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546921 · Cited by 8
Manukjan, G., Ripperger, T., Santer, L., Neuhoff, N. V., Ganser, A., Schambach, A., Schlegelberger, B., & Steinemann, D. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.011 · Cited by 5
Panuzzo, C., Volpe, G., Rocchietti, E. C., Casnici, C., Crotta, K., Crivellaro, S., Carrà, G., Lorenzatti, R., Peracino, B., Torti, D., et al. (2015) · Oncoscience · doi:10.18632/oncoscience.260 · Cited by 4
Sinha, S., Chakraborty, S., & Sengupta, A. (2020) · STAR Protocols · doi:10.1016/j.xpro.2020.100161 · Cited by 3
Self-citationThe genetics of chronic myelogenous leukaemia
May, P. C., Khorashad, J. S., Alikian, M., Perrotti, D., & Reid, A. G. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch7 · Cited by 1
Xiao, Y., Hu, H., Wang, H., Zhu, X., Zou, P., Chen, Z., Zhong, Z.-D., Li, W.-M., & You, Y. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.43
(2013) · De Gruyter eBooks · doi:10.1515/9783034610896.295
Wen, X. (2018) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v6i10.235
Fonctions oncogéniques de STAT5 : rôle dans la régulation du métabolisme oxydatif
Bourgeais, J. (2015) · theses.fr (ABES) · doi:10.70675/642a7bdcz3eb5z47fcza4fez4dd048c937e2
Rôle de la signalisation calcique dans la leucémie myéloïde chronique
Cabanas, H. (2016) · theses.fr (ABES) · doi:10.70675/c181bc1bz921ez4646zb959zc5a09cbd0a47
Metadata
- Authors
- Sengupta, A., Arnett, J., Dunn, S., Williams, D. A., & Cancelas, J. A.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- University of Cincinnati (US)
- Boston Children's Hospital (US)
- Stem Cell Biology Program, Division of Experimental Hematology & Cancer Biology, Cincinnati Children's Hospital Medical Center, OH;
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-07-08
- Volume
- 116
- Issue
- 1
- Pages
- 81-84
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2904584
- OpenAlex
- W2077305244
- Cited by
- 52
- References
- 19
- Citations by year
- 2022: 1 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 5 · 2014: 4 · 2013: 4 · 2012: 8
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL087159)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK062757)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- BCR-ABL, chronic myeloid leukemia, leukemia stem cells, hematopoietic stem cells, myeloproliferative neoplasms, apoptosis, cell proliferation, Rac1, hematopoietic microenvironment
- MeSH terms
- T-Cell Acute Lymphocytic Leukemia Protein 1, RAC2 GTP-Binding Protein, Animals, Cell Adhesion, Cell Movement, Female, Flow Cytometry, Hematopoietic Stem Cells, Male, Mice, Inbred C57BL, Mice, Transgenic, Proto-Oncogene Proteins, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Mice, Knockout, rac GTP-Binding Proteins, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
